Amyloid-Beta 42 and 40 — Two Peptide Isoforms, One Diagnostic Signal
Short placeholder: Aβ42 and Aβ40 differ by two C-terminal residues.
- 42 aa: Aβ42 length (Placeholder isoform note)
- 40 aa: Aβ40 length (Placeholder isoform note)
- Aβ42↑: Aggregation bias (Placeholder aggregation note)
- Aβ40>Aβ42: Plasma abundance (Placeholder abundance note)
Peptide isoform biology placeholder
Short placeholder describing APP cleavage generating Aβ42 and Aβ40 isoforms.
Correlating Plasma Biomarkers with CSF and Amyloid PET Findings
Short placeholder: plasma ratio tracks CSF and PET amyloid status.
- ~85%: Plasma-PET concordance (Placeholder concordance note)
- Strong: CSF correlation (Placeholder correlation note)
- EDTA plasma: Sample type (Placeholder sample note)
- Multiple: Preanalytical factors (Placeholder handling note)
Cross-modality correlation placeholder
Short placeholder on plasma versus CSF/PET biomarker concordance.
Calculating the Aβ42/40 Ratio — Methodology Overview
Short placeholder: ratio computed by dividing Aβ42 by Aβ40 concentration.
- 42/40: Formula (Placeholder formula note)
- pg/mL: Units (Placeholder units note)
- Internal std: Normalization (Placeholder normalization note)
- CV<10%: Assay precision (Placeholder precision note)
Ratio derivation placeholder
Short placeholder describing analytical steps for ratio calculation.
Diagnostic Cutoff Values and Clinical Interpretation
Short placeholder: cutoff thresholds classify amyloid pathology risk.
- >0.095: Normal cutoff (Placeholder cutoff note)
- <0.080: Abnormal cutoff (Placeholder cutoff note)
- 0.080–0.095: Borderline zone (Placeholder zone note)
- Screening: Clinical use (Placeholder use-case note)
Cutoff interpretation placeholder
Short placeholder on interpreting ratio values against diagnostic cutoffs.
Mass Spectrometry vs Immunoassay Detection Platforms
Short placeholder: platform choice affects sensitivity and precision.
- High: Mass spec precision (Placeholder platform note)
- High: Immunoassay throughput (Placeholder platform note)
- MS higher: Cost comparison (Placeholder cost note)
- Growing: Clinical adoption (Placeholder adoption note)
Platform comparison placeholder
Short placeholder comparing mass spectrometry and immunoassay platforms.
Placeholder key insight on platform selection for clinical labs.